Hangzhou Apeloa Medicine Research Institute Co. Ltd. and Apeloa Pharmaceutical Co. Ltd. have disclosed fibroblast growth factor receptor 4 (FGFR-4) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to epidermal growth factor receptor (EGFR)-binding moiety through linker reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.
Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.
Suzhou Zion Pharma Technology Co. Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer.
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
Medshine Discovery Inc. has presented furan fused ring-substituted glutarimides as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to androgen receptor-targeting moiety reported to be useful for the treatment of prostate cancer.
Shenzhen Forward Pharmaceutical Co. Ltd. has divulged estrogen receptor α (ERα) antagonists and/or degradation inducers reported to be useful for the treatment of cancer.
RSS